A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis

Part of paid clinical trials in Chula Vista, California.

Sponsor
Renibus Therapeutics, Inc.
Study ID
NCT07355062
Phase
PHASE3
Status
Recruiting

Conditions

  • CKD
  • Metabolic Acidosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Veverimer — DRUG
    Group 1: 9 g veverimer BID
  • Placebo — DRUG
    Group 2: 9 g PBO BID

Study Details

The purpose of this study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.

Key Dates

First listed
Jan 21, 2026
Start date
Jan 13, 2026
Status verified
Jul 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Veverimer
  • Placebo Comparator: Placebo

Primary Outcome Measure

Efficacy of Veverimer by measuring change in serum bicarbonate concentration (SBC) [ Time Frame: Visits: Screening to Day 168 ]

Central Contacts

Locations (22)

FacilityCityStateZIPSite coordinators
Study SiteChula VistaCalifornia91910-
Study SiteLos AngelesCalifornia90022-
Study SiteSacramentoCalifornia95817-
Study SiteSan DiegoCalifornia92111-
Study SiteAuroraColorado80045-
Study SiteEdgewaterFlorida32132-
Study SiteMiami SpringsFlorida33166-
Study SiteOrlandoFlorida32806-
Study SiteAugustaGeorgia30904-
Study SiteBoiseIdaho83706-
Study SiteChubbuckIdaho83201-
Study SiteIdaho FallsIdaho83401-
Study SiteChicagoIllinois60643-
Study SiteIndianapolisIndiana46202-
Study SiteLouisvilleKentucky40205-
Study SiteKansas CityMissouri64111-
Study SiteFresh MeadowsNew York11365-
Study SiteNew YorkNew York10016-
Study SiteWinston-SalemNorth Carolina27103-
Study SiteFort WorthTexas76110-
Study SiteHoustonTexas77054-
Study SiteSan AntonioTexas78212-

Find similar trials in Chula Vista, CA

Related Studies